Sabrina Foskey
Family · Brooklyn, NYNPI 1497748446
Payments from drug & device makers
Across 206 payments — averaging $37.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$924
- AstraZeneca$609
- Lilly USA, LLC$504
- Amgen$454
- Astellas Pharma US Inc$346
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,73399%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $1,801 |
| AbbVie | 10 | $924 |
| AstraZeneca | 18 | $609 |
| Lilly USA, LLC | 29 | $504 |
| Amgen(2 entities) | 10 | $454 |
| Astellas Pharma US Inc | 9 | $346 |
| Boehringer Ingelheim | 4 | $315 |
| Teva Pharmaceuticals USA, Inc. | 2 | $250 |
| Pfizer | 8 | $242 |
| Gilead | 2 | $199 |
| Merck | 9 | $198 |
| Bayer | 4 | $185 |
| GSK | 3 | $173 |
| Novartis | 8 | $171 |
| Mannkind Corporation | 6 | $151 |
| Madrigal Pharmaceuticals | 1 | $136 |
| Dexcom, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $120 |
| Mylan Specialty L.p. | 1 | $116 |
| Amarin Pharma, Inc. | 5 | $110 |
| Genentech USA, Inc. | 1 | $102 |
| Exact Sciences | 3 | $74 |
| Medtronic | 2 | $62 |
| Progenics Pharmaceuticals, Inc. | 1 | $50 |
| Biogen | 2 | $49 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Ardelyx, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Renalytix AI, Inc. | 1 | $25 |
| Phadia US Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $22 |
| Johnson & Johnson | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,802 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 34 | $51,278 |
| OzempicSemaglutide | 26 | $25,649 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $23,079 |
| JardianceEmpagliflozin | 21 | $21,086 |
| RybelsusSemaglutide | 16 | $16,246 |
| Diclofenac Sodium | 25 | $14,421 |
| FarxigaDapagliflozin Propanediol | 19 | $11,103 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,264 |
| VascepaIcosapent Ethyl | 14 | $6,118 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,143 |
| Novolog FlexpenInsulin Aspart | 11 | $3,176 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,387 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $1,564 |
| Atorvastatin Calcium | 140 | $1,347 |
| Rosuvastatin Calcium | 99 | $1,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $198 | $74,35761 claims |
| Novo NordiskOzempic, Rybelsus | $1,801 | $41,89542 claims |
| Boehringer IngelheimJardiance | $315 | $21,08621 claims |
| AstraZenecaFarxiga | $609 | $11,10319 claims |
| GSKBreo Ellipta | $173 | $7,26411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.